Get the Stockscreener App
37.25
0.32%
0.05
Exelixis Inc stock is traded at $37.25, with a volume of 430.49K.
It is up +0.32% in the last 24 hours and up +8.21% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$37.20
Open:
$37.25
24h Volume:
430.49K
Relative Volume:
0.18
Market Cap:
$10.44B
Revenue:
$2.08B
Net Income/Loss:
$466.92M
P/E Ratio:
23.88
EPS:
1.56
Net Cash Flow:
$404.94M
1W Performance:
-2.33%
1M Performance:
+8.21%
6M Performance:
+41.04%
1Y Performance:
+61.77%
1-Day Range:
$37.15
$37.73
1-Week Range:
$36.63
$40.02
52-Week Range:
$20.14
$40.02
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
37.26 | 10.44B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.54 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
678.02 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.05 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.79 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.47 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Exelixis at Leerink Global Healthcare Conference: Strategic Growth and Innovation - Investing.com UK
Exelixis at Barclays Healthcare Conference: Strategic Pipeline Progress By Investing.com - Investing.com UK
Exelixis stock hits 52-week high at $39.3 amid robust growth - Investing.com Australia
(EXEL) Trading Report - Stock Traders Daily
Global Prostate Cancer Market to Reach USD 29.2 Billion by 2035, Driven by Aging Population and Awareness | Future Market Insights, Inc. - GlobeNewswire Inc.
Proficio Capital Partners LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by US Bancorp DE - Defense World
Smartleaf Asset Management LLC Increases Holdings in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis, Inc. to Host Earnings Call - ACCESS Newswire
Equities Analysts Issue Forecasts for Exelixis Q1 Earnings - Defense World
Zacks Research Has Positive Outlook of Exelixis Q2 Earnings - Defense World
Exelixis EVP Haley Patrick sells $388,000 in stock - Investing.com India
Exelixis EVP Haley Patrick sells $388,000 in stock By Investing.com - Investing.com South Africa
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio - Yahoo Finance
Hepatocellular Carcinoma Treatment Market Size Report 2032 | - openPR
Peering Into Exelixis's Recent Short Interest - Benzinga
Truist Financial Corp Boosts Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now? - Insider Monkey
Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Principal Securities Inc. - Defense World
10 Best Immunology Stocks To Buy Now - Insider Monkey
Exelixis director Jack Wyszomierski sells $331,430 in stock By Investing.com - Investing.com Australia
Exelixis director Julie Smith sells $2.8 million in stock By Investing.com - Investing.com Australia
Exelixis director Jack Wyszomierski sells $331,430 in stock - Investing.com India
Exelixis director Julie Smith sells $2.8 million in stock - Investing.com
Exelixis Directors Execute Significant Stock Transactions - TradingView
BioInvent announces achievement of a research milestone event in its collaboration with Exelixis triggering a USD 1 million milestone payment - ACCESS Newswire
Exelixis focuses on future growth despite COSMIC-313 trial challenges - Yahoo Finance
Exelixis CFO Christopher Senner sells $1.06 million in stock By Investing.com - Investing.com South Africa
Exelixis CSO Aftab Dana sells shares worth $991,772 By Investing.com - Investing.com South Africa
When (EXEL) Moves Investors should Listen - Stock Traders Daily
Exelixis EVP Haley Patrick sells $1.95 million in company stock By Investing.com - Investing.com South Africa
Exelixis Stock: Executives Sell as Shares Near Peak - sharewise
Exelixis director Oliver Bob sells $694,600 in stock By Investing.com - Investing.com South Africa
Exelixis CFO Christopher Senner sells $1.06 million in stock - Investing.com India
Exelixis director Oliver Bob sells $694,600 in stock - Investing.com India
Exelixis Executives and Director Sell Shares - TradingView
Exelixis stock hits 52-week high at $37.63 amid robust growth By Investing.com - Investing.com South Africa
Exelixis stock hits 52-week high at $37.63 amid robust growth - Investing.com
Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors - Nasdaq
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March - Business Wire
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Wells Fargo Downgrades Exelixis to Equalweight From Overweight, Price Target is $36 - Marketscreener.com
Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks - Insider Monkey
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy? - MSN
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? - Benzinga India
Exelixis (EXEL) Stock Jumps Amid New Share Buyback Announcement - GuruFocus.com
Why Exelixis Stock Trounced the Market on Thursday - MSN
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):